Literature DB >> 21243020

Prostate cancer: treatment triggers for patients on active surveillance.

William M Hilton, Dipen J Parekh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21243020     DOI： 10.1038/nrurol.2010.235

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.

Authors:  Ashley E Ross; Stacy Loeb; Patricia Landis; Alan W Partin; Jonathan I Epstein; Anna Kettermann; Zhaoyong Feng; H Ballentine Carter; Patrick C Walsh
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

2.  NCCN clinical practice guidelines in oncology: prostate cancer early detection.

Authors:  Mark H Kawachi; Robert R Bahnson; Michael Barry; J Erik Busby; Peter R Carroll; H Ballentine Carter; William J Catalona; Michael S Cookson; Jonathan I Epstein; Ruth B Etzioni; Veda N Giri; George P Hemstreet; Richard J Howe; Paul H Lange; Hans Lilja; Kevin R Loughlin; James Mohler; Judd Moul; Robert B Nadler; Stephen G Patterson; Joseph C Presti; Antoinette M Stroup; Robert Wake; John T Wei
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

3.  Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?

Authors:  John J Coen; Adam S Feldman; Matthew R Smith; Anthony L Zietman
Journal:  BJU Int       Date:  2010-09-22       Impact factor: 5.588

4.  Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance.

Authors:  Andrew Loblaw; Liying Zhang; Adam Lam; Robert Nam; Alexandre Mamedov; Danny Vesprini; Laurence Klotz
Journal:  J Urol       Date:  2010-09-17       Impact factor: 7.450

5.  Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome.

Authors:  Stijn Roemeling; Monique J Roobol; Stijn H de Vries; Tineke Wolters; Claartje Gosselaar; Geert J L H van Leenders; Fritz H Schröder
Journal:  Eur Urol       Date:  2006-12-05       Impact factor: 20.096

Review 6.  Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Authors:  Patrick J Bastian; Ballentine H Carter; Anders Bjartell; Michael Seitz; Peter Stanislaus; Francesco Montorsi; Christian G Stief; Fritz Schröder
Journal:  Eur Urol       Date:  2009-03-06       Impact factor: 20.096

7.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

8.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Authors:  Laurence Klotz; Liying Zhang; Adam Lam; Robert Nam; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

Review 9.  Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.

Authors:  Daniel W Lin
Journal:  Urol Oncol       Date:  2009 May-Jun       Impact factor: 3.498

10.  Validation of the contemporary epstein criteria for insignificant prostate cancer in European men.

Authors:  Claudio Jeldres; Nazareno Suardi; Jochen Walz; Georg C Hutterer; Sascha Ahyai; Jean-Baptiste Lattouf; Alexander Haese; Markus Graefen; Andreas Erbersdobler; Hans Heinzer; Hartwig Huland; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2007-12-07       Impact factor: 20.096
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.